dostarlimab,carboplatin,paclitaxel
gsk
['gyn', 'dostarlimab', 'paclitaxel', 'carboplatin']
patients with primary advanced or recurrent #endometrialcancer were not adversely affected by the combination of dostarlimab-gxly + carboplatin/paclitaxel vs chemotherapy alone. #gyncsm #asco2023 | 
Oncology news and insights from leading researchers and cancer centers.